Daina Economidou1, Jeffrey W Dalley, Barry J Everitt. 1. Behavioral and Clinical Neuroscience Institute, Department of Experimental Psychology, University of Cambridge, Addenbrooke’s Hospital, United Kingdom. de244@cam.ac.uk
Abstract
BACKGROUND: Preventing relapse to drug use is a major challenge for drug addiction treatment. We have recently shown that impulsivity predating drug-taking increases the susceptibility to relapse to cocaine seeking and that treatment with the anti-impulsivity drug atomoxetine (ATO), a selective norepinephrine re-uptake inhibitor (norepinephrine transporter), prevents relapse. Here, we investigated further the effects of ATO on cue-maintained heroin and cocaine seeking and relapse and compared these effects with those of the anti-impulsivity stimulant drug methylphenidate (MPH). METHODS: Rats were trained to seek and self-administer cocaine or heroin under a second-order schedule of reinforcement. After acquisition of stable responding, groups of rats (n = 10-12) were treated, in a within-subject design, with either ATO or MPH (.3-3.0 mg/kg IP), and the effects on cocaine and heroin seeking were measured. The effects of ATO (.3-1.0 mg/kg) on cue-induced relapse to cocaine seeking after a 1-week period of abstinence were also studied. RESULTS: Atomoxetine significantly decreased both cue-controlled cocaine and heroin seeking, whereas MPH had no significant effect. Atomoxetine also significantly attenuated cue-induced relapse to cocaine seeking after abstinence. The effects of ATO were selective for cue-controlled drug-seeking, because it did not affect responding in the absence of the drug-paired cue; nor did it alter responding for oral sucrose, except minimally at the highest dose, or locomotor activity. CONCLUSIONS: Selective norepinephrine transporter inhibition by ATO might be an effective treatment for the prevention of relapse to both stimulant and opiate addiction. Copyright Â
BACKGROUND: Preventing relapse to drug use is a major challenge for drug addiction treatment. We have recently shown that impulsivity predating drug-taking increases the susceptibility to relapse to cocaine seeking and that treatment with the anti-impulsivity drug atomoxetine (ATO), a selective norepinephrine re-uptake inhibitor (norepinephrine transporter), prevents relapse. Here, we investigated further the effects of ATO on cue-maintained heroin and cocaine seeking and relapse and compared these effects with those of the anti-impulsivity stimulant drug methylphenidate (MPH). METHODS: Rats were trained to seek and self-administer cocaine or heroin under a second-order schedule of reinforcement. After acquisition of stable responding, groups of rats (n = 10-12) were treated, in a within-subject design, with either ATO or MPH (.3-3.0 mg/kg IP), and the effects on cocaine and heroin seeking were measured. The effects of ATO (.3-1.0 mg/kg) on cue-induced relapse to cocaine seeking after a 1-week period of abstinence were also studied. RESULTS: Atomoxetine significantly decreased both cue-controlled cocaine and heroin seeking, whereas MPH had no significant effect. Atomoxetine also significantly attenuated cue-induced relapse to cocaine seeking after abstinence. The effects of ATO were selective for cue-controlled drug-seeking, because it did not affect responding in the absence of the drug-paired cue; nor did it alter responding for oral sucrose, except minimally at the highest dose, or locomotor activity. CONCLUSIONS: Selective norepinephrine transporter inhibition by ATO might be an effective treatment for the prevention of relapse to both stimulant and opiate addiction. Copyright Â
Authors: Chiara Giuliano; Charles R Goodlett; Daina Economidou; Maria P García-Pardo; David Belin; Trevor W Robbins; Edward T Bullmore; Barry J Everitt Journal: Neuropsychopharmacology Date: 2015-06-05 Impact factor: 7.853
Authors: William J Kowalczyk; Jeremiah W Bertz; Landhing M Moran; Karran A Phillips; Udi E Ghitza; David H Epstein; Kenzie L Preston Journal: J Addict Med Date: 2017 Nov/Dec Impact factor: 3.702
Authors: John R Smethells; Natashia L Swalve; Lynn E Eberly; Marilyn E Carroll Journal: Psychopharmacology (Berl) Date: 2016-06-20 Impact factor: 4.530
Authors: Chloe J Jordan; Roxann C Harvey; Britahny B Baskin; Linda P Dwoskin; Kathleen M Kantak Journal: Drug Alcohol Depend Date: 2014-04-28 Impact factor: 4.492